In our study, fourteen of twenty-two (63.6%) PCNSL patients with a MYD88 and (or) CD79B mutation responded to treatment, whereas four of twenty-two (18.2%) patients with a CARD11 mutation did not respond to treatment. This evidence concerns the gene MYD88 and primary central nervous system lymphoma.